Navigation Links
New insight into aggressive childhood cancer
Date:1/5/2009

A new study reveals critical molecular mechanisms associated with the development and progression of human neuroblastoma, the most common cancer in young children. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell, may lead to development of future strategies for treatment of this aggressive and unpredictable cancer.

Neuroblastoma cells are derived from migratory neural crest cells that give rise to the peripheral sympathetic nervous system. During normal development, neural crest cells stop dividing and differentiate. However, neuroblastoma cells seem to have lost this capacity. Previous work has shown that amplification of the MYCN gene, which disrupts control of cell division and differentiation, is a strong predictor of poor prognosis in neuroblastoma.

"We speculated that genes that are expressed in a MYCN-dependent manner might be required specifically for the growth of MYCN-amplified neuroblastomas and that MYCN-amplified neuroblastomas might depend not only on N-Myc itself, but also on upstream regulatory factors or downstream target genes," explains senior study author, Dr. Martin Eilers, from the University of Wurzburg in Germany.

Dr. Eilers and colleagues performed a genetic screen of nearly 200 genes that are dependent on amplified MYCN in human neuroblastoma or are direct targets of Myc. The researchers found that the oncogene AURKA is required for growth of MYCN-amplified neuroblastoma cells, but not cells lacking amplified MYCN.

AURKA encodes the kinase Aurora A which is dysregulated in multiple types of cancer cells. Interestingly, Aurora A kinase activity was not required for N-Myc stabilization. Instead, elevated Aurora A levels in MYCN-amplified neuroblastoma cells interfered with the PI3-kinase-dependent and mitosis-specific degradation of N-Myc. This suggests that small molecule inhibitors of Aurora A kinase may not be effective at inhibiting the oncogenic functions of Aurora A.

"Our results show that stabilization of N-Myc is a critical oncogenic function of Aurora A in childhood neuroblastoma; the challenge will now be to find ways to interfere with this function in order to find new approaches for the therapy of these tumors," says Dr. Eilers. "The findings also suggest that the current views about why Aurora A is oncogenic may need to be re-evaluated."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Analog Devices Healthcare Team Participates in MIT Forum on Medical Device Industry : ADI's healthcare technology experts Patrick O'Doherty and Tom O'Dwyer offer insights on trends impacting next-generation medical electronic systems.
2. Researchers gain new insight on wonder of cell division
3. New Strong Knees DVD Offers Knee Pain Relief from Body Insight, Inc. and Gaiam Inc.
4. Insight deficit may explain denial in drug addiction
5. HIV Vaccine Failure Still Brings Insights
6. Researcher to provide new insight for treating vascular disease
7. Genetic Research Offers Insights Into Form of Malaria
8. New insights could lead to a better pneumococcal vaccine
9. Study offers new insights into teenagers and anxiety disorders
10. Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector
11. New Insight Into Most Common Forebrain Malformation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... July 23, 2017 , ... Better education to ... researchers presenting their work today at the American Orthopaedic Society for Sports ... the first one to prospectively document the association between sports specialization and lower ...
(Date:7/23/2017)... ... ... “Squiggy’s Outdoor Adventure”: a turtle’s backyard adventure that teaches the importance of ... Christian, a wife and mother to three amazing, and supportive, children. Paula lives ... God. She loves to tell stories to her children, play board games, bake, ...
(Date:7/21/2017)... ... 21, 2017 , ... "As a doctor of lung medicine managing chest diseases ... the market," said an inventor from Center Valley, Pa. "My idea is to improve ... He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient means of ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller Agency, a ... in the greater Birmingham area, is joining the Chris Hammond Youth Foundation in ... the region. , The Chris Hammond Youth Foundation maintains athletic facilities in rural ...
(Date:7/21/2017)... ... , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush University Medical ... Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine Leadership award ... prestigious award is given annually to honor those who have made a significant contribution ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology: